Citations

Clear

5 citation(s) found for "Lennon, Anne Marie".

Evidence that extra copies of chromosome 1q play a role in the early phases of pancreatic neoplasia
Douville, Christopher, Parksong, Jeeun , Molin, Marco Dal, Graham, Sarah , Greipp, Patricia T. , Knudson, Ryan A., Curtis, Samuel , Wang, Yuxuan , Dobbyn, Lisa , Popoli, Maria , Ptak, Janine , Silliman, Natalie , Romans, Katharine , Iacobuzio-Donahue, Christine A., Makoohon-Moore, Alvin P., Goggins, Michael, Hruban, Ralph H., Kiemen, Ashley, Bettegowda, Chetan, Kinzler, Kenneth W., Papadopoulos, Nickolas, Wood, Laura D, Vogelstein, B., Goggins, Michael , Hruban, Ralph H. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Bettegowda, Chetan , Douville, Christopher , Iacobuzio–Donahue, Christine A. , Wang, Yuxuan , Wood, Laura D. , Molin, Marco Dal , Douville, Christopher , Dal Molin, Marco , Knudson, Ryan, Iacobuzio-Donahue, Christine A , Lennon, Anne Marie , Goggins, Michael G , Hruban, Ralph H , Kiemen, Ashley , Bettegowda, Chetan , Kinzler, Kenneth W , Papadopoulos, Nickolas , Wood, Laura D , Vogelstein, Bert , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Greipp, Patricia T , Vogelstein, Bert

Mayo Clinic

Science Advances | February 20, 2026 | Volume: 12 | Issue: 8 | Pages: No page available

10.1126/sciadv.adx7501 | PMID 41719404 Get It

We searched for oncogenes activated by copy number increases using whole-genome sequencing data of 535 pancreatic ductal adenocarcinomas (PDACs). We found that gains of 1q were the second most common gain, occurring in 213 (39.8%) of PDACs. Single-cell analysis via fluorescence in situ hybridization on 33 cancers confirmed these results. A portion of 1q, rather than the entire 1q arm, was gained in 75 (14.0%) PDACs, allowing us to pinpoint two ~3-megabase regions of 1q that were nearly always gained. These two regions contained NCSTN and PSEN2 , genes that code two subunits of the γ-secretase complex. Evaluation of 267 precancerous lesions revealed that extra copies of NCSTN and PSEN2 were common (49%) in noninvasive neoplasms (high-grade pancreatic intraepithelial neoplasms), which are at relatively high risk for progression to PDACs, but uncommon (6%) in low-grade pancreatic intraepithelial neoplasia lesions, which have low malignant potential. We hypothesize that γ-secretase genes are genetically activated oncogenes in the early phases of pancreatic neoplasia.
A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising From Pancreatic Cysts
Wald, Abigail I. , Spagnolo, Daniel M. , Grupillo, Maria, Lai, Yi-Tak, O’Broin-Lennon, Anne Marie, Park, Walter G. , Pfau, Patrick , Kubiliun, Nisa , Easler, Jeffrey J. , Dam, Aamir, Mok, Shaffer , Wallace, Michael B. , Kumbhari, Vivek , Marsh, Wallis, Thakkar, Shyam , Fairley, Kimberly, Bhat, Yasser M., Nasr, John , Khalid, Asif , Fasanella, Kenneth, Chennat, Jennifer, Singh, Harkirat , Sarkaria, Savreet, Slivka, Adam, Gabbert, Charles, Sawas, Tarek , Tielleman, Thomas , Vanderveldt, Hendrikus Dutch, Tavakkoli, Anna , Smith, Katelyn, Hruban, Ralph H. , Paniccia, Alessandro , Zureikat, Amer H., Lee, Kenneth K. , Ongchin, Melanie , Zeh, Herbert J. , Minter, Rebecca M., He, Jin , Wallace, Michael B , Nikiforova, Marina N. , Melan, Melissa A. , Brand, Randall E. , McGrath, Kevin , Polanco, Patricio Marcelo , DeWitt, John M. , Boone, Brian A. , Afghani, Elham , Ramrakhiani, Sanjay , Skef, Wasseem , Thiruvengadam, Nikhil Ravi , Das, Rohit Kumar , Smith, Lynette M. , Bell, Phoenix , Nikiforov, Yuri E. , Singhi, Aatur Dilip

Mayo Clinic

Annals of Surgery | May 22, 2023 | Volume: 278 | Issue: 4 | Pages: e789-e797

10.1097/sla.0000000000005904 | PMID 37212422 Get It

Objective: We report the development and validation of a combined DNA/RNA next-generation sequencing (NGS) platform to improve the evaluation of pancreatic cysts. Background and Aims: Despite a multidisciplinary approach, pancreatic cyst classification, such as a cystic precursor neoplasm, and the detection of high-grade dysplasia and early adenocarcinoma (advanced neoplasia) can be challenging. NGS of preoperative pancreatic cyst fluid improves the clinical evaluation of pancreatic cysts, but the recent identification of novel genomic alterations necessitates the creation of a comprehensive panel and the development of a genomic classifier to integrate the complex molecular results. Methods: An updated and unique 74-gene DNA/RNA-targeted NGS panel (PancreaSeq Genomic Classifier) was created to evaluate 5 classes of genomic alterations to include gene mutations (e.g., KRAS, GNAS, etc.), gene fusions and gene expression. Further, CEA mRNA (CEACAM5) was integrated into the assay using RT-qPCR. Separate multi-institutional cohorts for training (n=108) and validation (n=77) were tested, and diagnostic performance was compared to clinical, imaging, cytopathologic, and guideline data. Results: Upon creation of a genomic classifier system, PancreaSeq GC yielded a 95% sensitivity and 100% specificity for a cystic precursor neoplasm, and the sensitivity and specificity for advanced neoplasia were 82% and 100%, respectively. Associated symptoms, cyst size, duct dilatation, a mural nodule, increasing cyst size, and malignant cytopathology had lower sensitivities (41–59%) and lower specificities (56–96%) for advanced neoplasia. This test also increased the sensitivity of current pancreatic cyst guidelines (IAP/Fukuoka and AGA) by >10% and maintained their inherent specificity. Conclusions: PancreaSeq GC was not only accurate in predicting pancreatic cyst type and advanced neoplasia but also improved the sensitivity of current pancreatic cyst guidelines.
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, Joshua D. , Li, Lu , Wang, Yuxuan , Thoburn, Christopher J. , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A. , Wong, Fay , Mattox, Austin K. , Hruban, Ralph H. , Wolfgang, Christopher L. , Molin, Marco Dal , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Browne, J. Dale, Tie, Jeanne , Wong, Hui‐Li , Mansfield, Aaron S. , Jen, Jin , Falconi, Massimo , Allen, Peter J. , Zhou, Shibin , Díaz, Luis A. , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Thoburn, Christopher , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A , Wong, Fay , Mattox, Austin , Wolfgang, Christopher L , Roden, Richard , Klein, Alison P , Ptak, Janine , Dobbyn, Lisa , Schaefer, Joy , Silliman, Natalie , Schoen, Robert E , Brand, Randall E , Tie, Jeanne , Wong, Hui-Li , Mansfield, Aaron S , Jen, Jin , Zhou, Shibin , Diaz, Luis A , Tomasetti, Cristian , Kinzler, Kenneth W , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Wang, Yuxuan , Afsari, Bahman , Goggins, Michael , Wang, Tian‐Li , Klein, Alison P. , Popoli, Maria , Vogelstein, Joshua T , Schoen, Robert E. , Brand, Randall E. , Gibbs, Peter , Hanash, Samir , Bettegowda, Chetan , Massimo, Falconi

Mayo Clinic

Science | January 18, 2018 | Volume: 359 | Issue: 6378 | Pages: 926-930

10.1126/science.aar3247 | PMID 29348365 Get It

SEEK and you may find cancer earlier Many cancers can be cured by surgery and/or systemic therapies when detected before they have metastasized. This clinical reality, coupled with the growing appreciation that cancer's rapid genetic evolution limits its response to drugs, have fueled interest in methodologies for earlier detection of the disease. Cohen et al. developed a noninvasive blood test, called CancerSEEK that can detect eight common human cancer types (see the Perspective by Kalinich and Haber). The test assesses eight circulating protein biomarkers and tumor-specific mutations in circulating DNA. In a study of 1000 patients previously diagnosed with cancer and 850 healthy control individuals, CancerSEEK detected cancer with a sensitivity of 69 to 98% (depending on cancer type) and 99% specificity. Science , this issue p. 926 ; see also p. 866
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
Javed, Ammar A. , Thoburn, Christopher J. , Wong, Fay , Tie, Jeanne , Allen, Peter J., Schattner, Mark , Petersen, Gloria M. , Hong, Seung‐Mo , Falconi, Massimo , Weiss, Matthew J. , Ahuja, Nita , He, Jin , Makary, Martin A. , Molin, Marco Dal , Li, Lu , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Hruban, Ralph H. , Wolfgang, Christopher L. , Papadopoulos, Nickolas , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Thoburn, Christopher , Javed, Ammar A , Tie, Jeanne , Lennon, Anne Marie , Cohen, Joshua D. , Gibbs, Peter , Schmidt, Christian Max , YIP-SCHNEIDER, Michele T. , Brand, Randall E. , Singhi, Aatur Dilip , Kim, Song Cheol , Doglioni, Claudio , Maitra, Anirban , Hanash, Samir , Wang, Yuxuan , Schaefer, Joy , Popoli, Maria , Goggins, Michael , Klein, Alison P. , Tomasetti, Cristian , Massimo, Falconi

Mayo Clinic

Proceedings of the National Academy of Sciences | September 5, 2017 | Volume: 114 | Issue: 38 | Pages: 10202-10207

10.1073/pnas.1704961114 | PMID 28874546 Get It

Significance Few patients with pancreatic cancer survive longer than 5 y, in part because most patients are identified only after their disease has progressed to an advanced stage. In this study, we show how combining mutations in circulating tumor DNA (ctDNA) with protein markers can result in a screening test with improved sensitivity while retaining specificity. The combination of the ctDNA and protein markers was superior to any single marker. Moreover, the combination detected nearly two-thirds of pancreatic cancers that had no evidence of distant metastasis at the time of surgical resection. The strategy may represent an approach to detect cancers of many types at an earlier stage.
Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts
Knight, Spencer, Topazian, Mark , Kamel, Ihab R. , Lennon, Anne Marie , Borges, Michael , Young, Angela , Fujiwara, Sho , Seike, Junro , Eshleman, James R. , Hruban, Ralph H. , Kanda, Mitsuro , Syngal, Sapna , Farrell, James J. , Lee, Jeffrey D. , Canto, Marcia Irene , Goggins, Michael , Lennon, Anne Marie

Mayo Clinic

Gut | August 2, 2012 | Volume: 62 | Issue: 7 | Pages: 1024-1033

10.1136/gutjnl-2012-302823 | PMID 22859495 Get It

Objective Pancreatic cysts are commonly detected in patients undergoing pancreatic imaging. Better approaches are needed to characterise these lesions. In this study we evaluated the utility of detecting mutant DNA in secretin-stimulated pancreatic juice. Design Secretin-stimulated pancreatic juice was collected from the duodenum of 291 subjects enrolled in Cancer of the Pancreas Screening trials at five US academic medical centres. The study population included subjects with a familial predisposition to pancreatic cancer who underwent pancreatic screening, and disease controls with normal pancreata, chronic pancreatitis, sporadic intraductal papillary mucinous neoplasm (IPMN) or other neoplasms. Somatic GNAS mutations (reported prevalence ∼66% of IPMNs) were measured using digital high-resolution melt-curve analysis and pyrosequencing. Results GNAS mutations were detected in secretin-stimulated pancreatic juice samples of 50 of 78 familial and sporadic cases of IPMN(s) (64.1%), 15 of 33 (45.5%) with only diminutive cysts (<5 mm), but none of 57 disease controls. GNAS mutations were also detected in five of 123 screened subjects without a pancreatic cyst. Among 97 subjects who had serial pancreatic evaluations, GNAS mutations detected in baseline juice samples predicted subsequent emergence or increasing size of pancreatic cysts. Conclusion Duodenal collections of secretin-stimulated pancreatic juice from patients with IPMNs have a similar prevalence of mutant GNAS to primary IPMNs, indicating that these samples are an excellent source of mutant DNA from the pancreas. The detection of GNAS mutations before an IPMN is visible suggests that analysis of pancreatic juice has the potential to help in the risk stratification and surveillance of patients undergoing pancreatic screening.